Volcano to Highlight New Technologies and Clinical Study Results at TCT 2012

Volcano to Highlight New Technologies and Clinical Study Results at TCT 2012 PR Newswire SAN DIEGO, Oct. 20, 2012 SAN DIEGO, Oct. 20, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced plans to highlight its functional measurement technologies and clinical study results related to Intravascular Ultrasound (IVUS) catheters and Fractional Flow Reserve (FFR) guide wires, at the Transcatheter Cardiovascular Therapeutics (TCT) conference being held in Miami from October 22nd - 26th, 2012. "In keeping with Volcano's commitment to innovation in providing solutions for complex indications, we will be highlighting our advances in Functional Management and a suite of new products designed to address the most complex clinical indications," commented Scott Huennekens, president and chief executive officer of Volcano. "As key healthcare reforms are now being implemented, it is important, now more than ever, that physicians have the right tools to thoroughly evaluate patients, not only to guide treatment pathways, but to provide evidence supporting their decisions. With the insight our technologies provide, Volcano can help physicians and healthcare institutions answer the growing demand for truly personalized medicine that is appropriate, evidence-based, and accountable.